TARE allows for a 44% chance of response, 30% downstaging, and 23% probability of permitting liver transplantation in intermediate and advanced HCC.

¹⁸F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic ¹⁸F-FDG PET/CT for CUP patients.

Patients with a mean tumour absorbed dose lower than the best cut-off value of 10.6 Gy after first cycle had a significantly shorter median PFS (HR 8.6, 95% CI: 2–37).

Salvage RT is associated with delayed clinical progression in patients with post radical prostatectomy biochemical recurrence and negative PSMA PET/CT (HR: 0.2, p=0.03). Median follow-up was 39 months.

¹⁶¹Tb-labeled DOTATATE and DOTA-LM3 delivered 3.6 and 3.8 times higher doses to the cell nucleus, respectively, than their ¹⁷⁷Lu-labeled counterparts. This increased nucleus-absorbed dose was mainly due to the additional emission of IC and not Auger electrons by ¹⁶¹Tb.

Meta-analysis of 27 studies involving 1,365 patients. Treatment-naïve patients had significantly better survival outcomes after TARE.

Pediatric PTC patients, including those with LN metastases, may achieve excellent long-term outcomes without RAI.

Baseline tumor SUV_mean from PSMA PET is the strongest predictor of treatment efficacy with ¹⁷⁷Lu-PSMA-617 in mCRPC, with higher SUVmean values correlating with improved outcomes in the VISION trial.

Authors discuss the advancements in NET management, likening radioligands to "midi-chlorians" from the Star Wars series, and emphasize the potential of novel imaging and therapeutic agents in improving personalized care.

Hydroxyurea, gemcitabine and triapine all increased cell size, SSTR2A expression, and ¹⁷⁷Lu-DOTA-TATE uptake, whilst reducing cell metabolic viability in U2OS + SSTR2A cells when compared to ¹⁷⁷Lu-DOTA-TATE monotherapy.

PRRT with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE demonstrated a 57% disease control rate in meningioma patients with radiologic recurrence after standard therapies. Median PFS and OS were 16 and 36 months, respectively. PRRT was well tolerated and shows potential as a retreatment option.